Neurodegenerative Disease: The Growing Market for Drugs used in the Treatment of Alzheimer's, Parkinson's and other Neurodegenerative Conditions

  • ID: 314626
  • Report
  • 350 Pages
  • IMS Health
1 of 4
Neurodegenerative diseases are destined to become the next great health crusade over the next several decades. This will support sustaintable long-term sales growth of NDD products: the collective total sales of the eight markets reviewed in this report are set to more than double in size to over $10bn by 2013.

The market for products for Alzheimer's disease and Parkinson's disease is set to more than double in size over the coming decade. The growth of these therapy areas will be affected by a range of factors:

- The aging of the global population and more accurate diagnosis will foster market increases
- In a class yet to be affected by generic competition, growth in the Alzheimer's market will be driven by the launch of new types of drugs including GABA receptor modulators, anti-amyloid protein agents and nicotinic and cholinergic receptor agonists
- Vaccines and neuroprotective therapies will also play a role in the development of the Alzheimer's market
- Growth in the Parkinson's market will in the medium to long term be driven by the launch of glutamate receptor modulators, dopamine receptor agonists and reuptake inhibitors, and andrenergic and adenosine antagonists
- However, this market will be impacted heavily in the shorter term by loss of patent protection for leading dopamine agonists
- Payers' resistance to increasing healthcare costs will stimulate the growth of generics, as well as budget caps, price limits and non-approvals of expensive treatments across the neurodegenerative disease market
- Nevertheless, new products will enter this market at a premium relative to their effectiveness when compared with established treatments

Comprehensive coverage including:

- Detailed profiles of 10 leading manufacturers and the position of neurodegenerative disease products in their portfolios
- Detailed analysis of both the Alzheimer's disease and Parkinson's disease markets, including discussion of past, current and future performance
- Assessment of the role of AChE inhibitors in driving the recently-formed Alzheimer's disease market
- The impact of the arrival of the first of the next generation NMDA receptor antagonists on this market
- Assessment of the role of dopamine agonists as first-line therapy for Parkinson's disease
- The role played by COMT inhibitors as adjunctive therapies alongside levodopa in Parkinson's treatment
- The use of amantadine and anticholinergic drugs for symptomatic relief
- The impact of the arrival of the second-generation MAO-B inhibitor, rasagiline, on the Parkinson's market
- The impact of patent expiries
- Detailed profiles of 15 leading products – including clinical data, licensing, lifecycle management, competition, prospects
- Compounds in R&D - with drug profiles and analysis

Plus background information on neurodegenerative disease, with specific reference to Alzheimer's and Parkinson's disease:

- Epidemiology of neurodegenerative disease by region, selected countries, type, age, sex, ethnic group [see sample]
- Disease overview - definitions, classifications, risk factors, diagnosis and treatment, costs and consequences of neurodegenerative diseases

Key Findings

- Neurodegenerative disease (NDD) is a general term for a number of disorders that have different symptoms and effects, all of which act through the mechanism of compromising the brain's capacity to control itself or the body by damaging cells known as neurons that facilitate normal brain function

- Alzheimer's disease (AD) is the world's leading cause of dementia and the most prevalent NDD. 50-75% of dementia is estimated to be caused by this disease

- Parkinson's disease (PD) is the world's second commonest form of NDD. Parkinsonism is a term for a group of disorders that result in symptoms similar to those seen in classic PD NDDs are primarily diseases of older people. With the world's population living longer, the numbers of sufferers are set to rise over the next several decades

- NDDs constitute a disease category that the World Health Organization (WHO) calculates will become the world's second leading cause of death by the year 2040, overtaking cancer

- Onset of AD most commonly occurs after 65 years of age (only 2% of dementia occurs in patients under 65)

- Prevalence of AD is slightly higher in women than in men, but almost twice as many women live with dementia because of their longer life expectancy

- AD is usually divided into three distinct phases: mild, moderate and severe (also known as early-stage, mid-stage and late-stage) AD

- Onset of PD most commonly occurs after 60 years of age, but an early-onset form of the disease can strike those aged under 40

- Prevalence is slightly higher in men than in women

- Total NDD product sales more than doubled in dollar terms in the period 2000-2004 to reach almost $5.7bn

- The US is the world's single largest NDD products market, worth nearly $2.3bn in 2004. Japan and Germany were the next biggest markets

- In 2003, AD treatments overtook PD treatments to become the largest contributing element in the overall NDD products market

- Patients are most commonly treated for AD with a class of drugs known as AChE inhibitors, such as Eisai/Pfizer's Aricept (donepezil)

- Aricept is the global number-one AD drug, worth $1.8bn in 2004. The next largest brand was Novartis' Exelon (rivastigmine), another AChE inhibitor
READ MORE
Note: Product cover images may vary from those shown
2 of 4
DATA DEFINITIONS AND SOURCES 1

Sales Data and Exchange Rates 1
Other Sources 1
Manufacturers and Brands 1
The MIDAS Database System 2

EXECUTIVE SUMMARY 3
Neurodegenerative Disease Market Key Findings 3
Anti-Alzheimer Products Market Key Findings 4
Anti-Parkinson Products Market Key Findings 5
The Threat of NDD 7
The Threat of Alzheimer's Disease 8
The Threat of Parkinson's Disease 9
Treatment 10
Treatment of Alzheimer's Disease 10
Treatment of Parkinson's Disease 11
The Global Market 15
Anti-Alzheimer Products Market by Region 15
Anti-Parkinson Products Market by Region 16
Key AD Product Manufacturers 16
Key PD Product Manufacturers 17
Leading Anti-Alzheimer Products 18
Leading Anti-Parkinson Products 18
New AD Treatments 19
New PD Treatments 19
Late-stage R&D 19
Anti-Alzheimer Products Pipeline 20
Anti-Parkinson Products Pipeline 21
The Future 22
The Future of the Anti-Alzheimer Products Market 23
The Future of the Anti-Parkinson Products Market 24

1.0 DISEASE OVERVIEW 26
1.1 Definition of Neurodegenerative Disease 26
1.1.1 Normal Brain Function 26
1.1.2 Alzheimer's Disease and Down's Syndrome 27
1.1.3 Parkinson's Disease and Parkinsonism 28
1.1.4 Huntington's Disease 29
1.1.5 Other Neurodegenerative Diseases 30
1.1.6 Risk Factors 31
1.1.7 Consequences of Neurodegenerative Disease 33
1.2 Diagnosis & Treatment 33
1.2.1 Diagnosis and Treatment of Alzheimer's Disease 34
1.2.2 Diagnosis and Treatment of Parkinson's Disease and Parkinsonism 37
1.2.3 Diagnosis and Treatment of Other Neurodegenerative Diseases 40
1.3 The Costs of Neurodegenerative Disease 41
1.3.1 The Cost-effectiveness of NDD Products 42

2.0 EPIDEMIOLOGY 43
2.1 Neurological Care Resources 43
2.2 The Global Burden of Neurodegenerative Diseases 45
2.2.1 Impact of Alzheimer's Disease on Mortality and Life Expectancy 47
2.2.2 Impact of Parkinson's Disease on Mortality and Life Expectancy 49
2.2.3 Epidemiology in Europe 51
2.2.4 Epidemiology in the US 56
2.2.5 Epidemiology in Japan 58

3.0 NEURODEGENERATIVE DISEASE DRUG CLASSES 60
3.1 Global Drug Classes 60
3.1.1 Anti-Alzheimer Products 61
3.1.2 Anti-Parkinson Products 61
3.2 Definition of Anti-Alzheimer Drug Sub-classes 61
3.2.1 AChE inhibitors 61
3.2.2 Memantine 63
3.3 Definition of Anti-Parkinson Drug Sub-classes 64
3.3.1 Levodopa and Dopamine Agonists 64
3.3.2 COMT inhibitors 68
3.3.3 MAO-B inhibitors 68
3.3.4 Amantadine 69
3.3.5 Anticholinergics 69
3.3.6 Combination Therapies 70

4.0 LEADING PRODUCTS IN THE GLOBAL MARKET 71
4.1 Global Product Sales 71
4.1.1 Leading Global Anti-Alzheimer Products 72
4.1.2 Top 20 Global Anti-Parkinson Products 76
4.2 Anti-Alzheimer Product Profiles 82
4.2.1 Aricept 82
4.2.2 Exelon 87
4.2.3 Reminyl/Razadyne 90
4.2.4 Namenda 93
4.2.5 Ebixa 97
4.3 Anti-Parkinson Product Profiles 101
4.3.1 Sifrol/Mirapex 101
4.3.2 Cabaser 104
4.3.3 ReQuip 106
4.3.4 Madopar 109
4.3.5 Sinemet 111
4.3.6 Permax 113
4.3.7 Comtan 114
4.3.8 Stalevo 116
4.3.9 FP 118
4.3.10 Akineton 119

5.0 LEADING GLOBAL MANUFACTURERS 122
5.1 Global Neurodegenerative Disease Product Manufacturer Sales 122
5.2 Global Anti-Alzheimer Product Manufacturer Sales 123
5.2.1 Total Global Sales by Manufacturer 123
5.3 Global Anti-Parkinson Product Manufacturer Sales 126
5.3.1 Total Global Sales by Manufacturer 126
5.4 Sales Comparisons of the Leading NDD Manufacturers 131
5.4.1 Sales Comparison of Leading Anti-Alzheimer Product Manufacturers 131
5.4.2 Sales Comparison of Leading Anti-Parkinson Product Manufacturers 131

5.5 Profiles of the Leading Manufacturers 132
5.5.1 Boehringer Ingelheim 132
5.5.2 Eisai 139
5.5.3 Forest Laboratories 145
5.5.4 GlaxoSmithKline 151
5.5.5 Johnson & Johnson 160
5.5.6 Lilly 166
5.5.7 Lundbeck 173
5.5.8 Novartis 180
5.5.9 Pfizer 188
5.5.10 Roche 197

6.0 OVERVIEW OF NATIONAL MARKETS FOR NEURODEGENERATIVE DISEASE PRODUCTS 206

6.1 Neurodegenerative Disease Product Sales in Selected Markets 206
6.2 Anti-Alzheimer Product Sales in Selected Markets 207
6.2.1 Comparison of Anti-Alzheimer Product Sales in Selected Markets 207
6.2.2 Anti-Alzheimer Product Sales as a Proportion of National
Pharmaceutical Markets 209
6.3 Anti-Parkinson Product Sales in Selected Markets 209
6.3.1 Comparison of Anti-Parkinson Product Sales in Selected Markets 210
6.3.2 Anti-Parkinson Product Sales as a Proportion of National
Pharmaceutical Markets 211

7.0 THE BRAZILIAN MARKET 212
7.1 Pharmaceutical Market Background 212
7.2 The Brazilian Anti-Alzheimer Products Market 214
7.2.1 Leading Products in Brazil 214
7.2.2 Leading Manufacturers in Brazil 215
7.3 The Brazilian Anti-Parkinson Products Market 216
7.3.1 Leading Products in Brazil 216
7.3.2 Leading Manufacturers in Brazil 219

8.0 THE CANADIAN MARKET 222
8.1 Pharmaceutical Market Background 222
8.2 The Canadian Anti-Alzheimer Products Market 225
8.2.1 Leading Products in Canada 225
8.2.2 Leading Manufacturers in Canada 226
8.3 The Canadian Anti-Parkinson Products Market 227
8.3.1 Leading Products in Canada 227
8.3.2 Leading Manufacturers in Canada 230

9.0 THE FRENCH MARKET 233
9.1 Pharmaceutical Market Background 233
9.2 The French Anti-Alzheimer Products Market 236
9.2.1 Leading Products in France 236
9.2.2 Leading Manufacturers in France 237
9.3 The French Anti-Parkinson Products Market 238
9.3.1 Leading Products in France 238
9.3.2 Leading Manufacturers in France 241

10.0 THE GERMAN MARKET 244
10.1 Pharmaceutical Market Background 244
10.2 The German Anti-Alzheimer Products Market 247
10.2.1 Leading Products in Germany 247
10.2.2 Leading Manufacturers in Germany 249
10.3 The German Anti-Parkinson Products Market 250
10.3.1 Leading Products in Germany 250
10.3.2 Leading Manufacturers in Germany 253

11.0 THE ITALIAN MARKET 256
11.1 Pharmaceutical Market Background 256
11.2 The Italian Anti-Alzheimer Products Market 259
11.2.1 Leading Products in Italy 259
11.2.2 Leading Manufacturers in Italy 260
11.3 The Italian Anti-Parkinson Products Market 261
11.3.1 Leading Products in Italy 261
11.3.2 Leading Manufacturers in Italy 264

12.0 THE JAPANESE MARKET 266
12.1 Pharmaceutical Market Background 266
12.2 The Japanese Anti-Alzheimer Products Market 271
12.2.1 Leading Products in Japan 271
12.2.2 Leading Manufacturers in Japan 272
12.3 The Japanese Anti-Parkinson Products Market 272
12.3.1 Leading Products in Japan 272
12.3.2 Leading Manufacturers in Japan 275

13.0 THE MEXICAN MARKET 277
13.1 Pharmaceutical Market Background 277
13.2 The Mexican Anti-Alzheimer Products Market 279
13.2.1 Leading Products in Mexico 279
13.2.2 Leading Manufacturers in Mexico 281
13.3 The Mexican Anti-Parkinson Products Market 281
13.3.1 Leading Products in Mexico 281
13.3.2 Leading Manufacturers in Mexico 284

14.0 THE SPANISH MARKET 286
14.1 Pharmaceutical Market Background 286
14.2 The Spanish Anti-Alzheimer Products Market 289
14.2.1 Leading Products in Spain 289
14.2.2 Leading Manufacturers in Spain 291
14.3 The Spanish Anti-Parkinson Products Market 292
14.3.1 Leading Products in Spain 292
14.3.2 Leading Manufacturers in Spain 295

15.0 THE UK MARKET 297
15.1 Pharmaceutical Market Background 297
15.2 The UK Anti-Alzheimer Products Market 302
15.2.1 Leading Products in the UK 302
15.2.2 Leading Manufacturers in the UK 303
15.3 The UK Anti-Parkinson Products Market 304
15.3.1 Leading Products in the UK 304
15.3.2 Leading Manufacturers in the UK 306

16.0 THE US MARKET 309
16.1 Pharmaceutical Market Background 309
16.2 The US Anti-Alzheimer Products Market 314
16.2.1 Leading Products in the US 314
16.2.2 Leading Manufacturers in the US 315
16.3 The US Anti-Parkinson Products Market 316
16.3.1 Leading Products in the US 316
16.3.2 Leading Manufacturers in the US 319

17.0 RESEARCH & DEVELOPMENT 322
17.1 Anti-Alzheimer Products in Development 322
17.1.1 Profiles of Leading Anti-Alzheimer Products in Development 324
17.2 Anti-Parkinson Products in Development 341
17.2.1 Profiles of Leading Anti-Parkinson Products in Development 343

18.0 THE FUTURE OF NEURODEGENERATIVE DISEASE TREATMENTS MARKETS 359
18.1 Aggregate Event-based Forecasts 359
18.1.1 Anti-Alzheimer Product Forecasts 360
18.1.2 Anti-Parkinson Product Forecasts 362

18.2 Canada 364
18.2.1 Diagnosis and Prescribing Profiles 364
18.2.2 Evented Forecasts 364
18.2.3 The Future of the Canadian Anti-Alzheimer Products Market 365
18.2.4 The Future of the Canadian Anti-Parkinson Products Market 366

18.3 France 367
18.3.1 Diagnosis and Prescribing Profiles 367
18.3.2 Evented Forecasts 367
18.3.3 The Future of the French Anti-Alzheimer Products Market 368
18.3.4 The Future of the French Anti-Parkinson Products Market 369

18.4 Germany 369
18.4.1 Diagnosis and Prescribing Profiles 369
18.4.2 Evented Forecasts 370
18.4.3 The Future of the German Anti-Alzheimer Products Market 371
18.4.4 The Future of the German Anti-Parkinson Products Market 371

18.5 Italy 372
18.5.1 Diagnosis and Prescribing Profiles 372
18.5.2 Evented Forecasts 372
18.5.3 The Future of the Italian Anti-Alzheimer Products Market 373
18.5.4 The Future of the Italian Anti-Parkinson Products Market 374

18.6 Japan 374
18.6.1 Diagnosis and Prescribing Profiles 374
18.6.2 Evented Forecasts 374
18.6.3 The Future of the Japanese Anti-Alzheimer Products Market 376
18.6.4 The Future of the Japanese Anti-Parkinson Products Market 376

18.7 Spain 377
18.7.1 Diagnosis and Prescribing Profiles 377
18.7.2 Evented Forecasts 377
18.7.3 The Future of the Spanish Anti-Alzheimer Products Market 378
18.7.4 The Future of the Spanish Anti-Parkinson Products Market 378

18.8 The UK 379
18.8.1 Diagnosis and Prescribing Profiles 379
18.8.2 Evented Forecasts 379
18.8.3 The Future of the UK Anti-Alzheimer Products Market 380
18.8.4 The Future of the UK Anti-Parkinson Products Market 381

18.9 The US 382
18.9.1 Diagnosis and Prescribing Profiles 382
18.9.2 Evented Forecasts 382
18.9.3 The Future of the US Anti-Alzheimer Products Market 383
18.9.4 The Future of the US Anti-Parkinson Products Market 384

18.10 The Future of the Global Neurodegenerative Disease Products Markets 385
18.10.1 The Future of the Global Anti-Alzheimer Products Market 385
18.10.2 The Future of the Global Anti-Parkinson Products Market 387

19.0 OPINIONS ON THE FUTURE OF THE NEURODEGENERATIVE DISEASE PRODUCTS MARKET 389

19.1 NICE Committee Holds Key to Development of UK
Anti-Alzheimer Products Market 389
19.2 What is the Future of Parkinson's Patient Care in the UK? 392
19.3 The Challenges and Holy Grails of Alzheimer's research 394
19.4 Future Pricing Trends in the EU Market for Neurodegenerative Disease Products 396
19.5 The Future of the US Neurodegenerative Disease Products Markets 398
19.6 The Current and Future State of Parkinson's Disease Care in the US 400
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll